Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.
Yojiro HashiguchiKei MuroYutaka SaitoYoshinori ItoYoichi AjiokaTetsuya HamaguchiKiyoshi HasegawaKinichi HottaHideyuki IshidaMegumi IshiguroSoichiro IshiharaYukihide KanemitsuYusuke KinugasaKeiko MurofushiTakako Eguchi NakajimaShiro OkaToshiaki TanakaHiroya TaniguchiAkihito TsujiKeisuke UeharaHideki UenoTakeharu YamanakaKentaro YamazakiMasahiro YoshidaTakayuki YoshinoMichio ItabashiKentaro SakamakiKeiji SanoYasuhiro ShimadaShinji TanakaHiroyuki UetakeShigeki YamaguchiNaohiko YamaguchiHirotoshi KobayashiKeiji MatsudaKenjiro KotakeKenichi Sugiharanull nullPublished in: International journal of clinical oncology (2019)
The number of deaths from colorectal cancer in Japan continues to increase. Colorectal cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of treatments was performed, with corrections and additions made based on knowledge acquired since the 2016 version (drug therapy) and the 2014 version (other treatments). The Japanese Society for Cancer of the Colon and Rectum guidelines 2019 for the treatment of colorectal cancer (JSCCR guidelines 2019) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment and to deepen mutual understanding between healthcare professionals and patients by making these guidelines available to the general public. These guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Controversial issues were selected as clinical questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSCCR guidelines 2019.
Keyphrases
- clinical practice
- end stage renal disease
- health insurance
- healthcare
- chronic kidney disease
- newly diagnosed
- emergency department
- systematic review
- squamous cell carcinoma
- deep learning
- total knee arthroplasty
- machine learning
- mental health
- prognostic factors
- peritoneal dialysis
- young adults
- papillary thyroid
- patient reported outcomes
- cell therapy
- affordable care act